Melqart Asset Management UK Ltd Sells 75,348 Shares of Amedisys, Inc. (NASDAQ:AMED)

Melqart Asset Management UK Ltd reduced its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 21.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 275,972 shares of the health services provider's stock after selling 75,348 shares during the quarter. Amedisys comprises about 2.4% of Melqart Asset Management UK Ltd's investment portfolio, making the stock its 14th largest holding. Melqart Asset Management UK Ltd owned 0.84% of Amedisys worth $26,634,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMED. KBC Group NV bought a new stake in Amedisys in the third quarter worth about $63,000. Innealta Capital LLC bought a new stake in Amedisys in the second quarter worth about $64,000. Signaturefd LLC raised its position in Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock worth $104,000 after acquiring an additional 530 shares in the last quarter. CWM LLC raised its position in Amedisys by 14.5% in the third quarter. CWM LLC now owns 2,190 shares of the health services provider's stock worth $211,000 after acquiring an additional 277 shares in the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new stake in Amedisys during the 3rd quarter worth about $243,000. 94.36% of the stock is currently owned by institutional investors.

Amedisys Trading Down 1.5 %

NASDAQ AMED traded down $1.29 on Wednesday, hitting $84.98. 1,362,268 shares of the company were exchanged, compared to its average volume of 369,084. The company's 50 day moving average price is $94.41 and its 200-day moving average price is $95.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market capitalization of $2.78 billion, a P/E ratio of 34.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.73. Amedisys, Inc. has a twelve month low of $84.06 and a twelve month high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $587.67 million for the quarter, compared to analysts' expectations of $586.75 million. During the same period last year, the firm earned $0.98 EPS. The company's revenue was up 5.7% compared to the same quarter last year. Analysts predict that Amedisys, Inc. will post 4.53 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.